Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

0.9859 -0.0241 (-2.39%)
Streaming Delayed Price Updated: 10:46 AM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 368,041
Open 1.010
Bid (Size) 0.9851 (300)
Ask (Size) 0.9988 (500)
Prev. Close 1.010
Today's Range 0.9750 - 1.010
52wk Range 0.3258 - 1.510
Shares Outstanding 46,166,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Registration Momentum Builds Across the Oncology Pipeline
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
+0.2%
+0.2%
1 Month
+14.2%
+14.2%
3 Month
-0.4%
-0.4%
6 Month
-24.7%
-24.7%
1 Year
+60.9%
+60.9%

More News

Read More
News headline image
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug ↗
Via Stocktwits
News headline image
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
From Equity Insider
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
From USA News Group
Via GlobeNewswire
News headline image
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
From USA News Group
Via GlobeNewswire
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
From Equity Insider
Via GlobeNewswire
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE CHOKE POINT: 5 Assets That Control the Bottleneck
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
From USA News Group
Via GlobeNewswire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
From USA News Group
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
From USA News Group
Via GlobeNewswire
News headline image
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
From USA News Group
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
From Oncolytics Biotech Inc.
Via Business Wire

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Shares publicly traded?
Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
Oncolytics Biotech Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONCY on the Nasdaq Stock Market
What is the current price of Oncolytics Biotech Inc. - Common Shares?
The current price of Oncolytics Biotech Inc. - Common Shares is 0.9859
When was Oncolytics Biotech Inc. - Common Shares last traded?
The last trade of Oncolytics Biotech Inc. - Common Shares was at 03/12/26 10:46 AM ET
What is the market capitalization of Oncolytics Biotech Inc. - Common Shares?
The market capitalization of Oncolytics Biotech Inc. - Common Shares is 45.52M
How many shares of Oncolytics Biotech Inc. - Common Shares are outstanding?
Oncolytics Biotech Inc. - Common Shares has 46M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.